Gilead Sciences GILD Income Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $29.44B+2.4% | $28.75B+6.0% | $27.12B-0.6% | $27.28B-0.1% | ||
| $6.23B-0.3% | $6.25B-3.8% | $6.5B+14.9% | $5.66B-14.3% | ||
| $23.21B+3.1% | $22.5B+9.1% | $20.62B-4.7% | $21.62B+4.4% | ||
| 78.8%+0.6pp | 78.3%+2.2pp | 76%-3.2pp | 79.3%+3.4pp | ||
| $5.77B-5.2% | $6.09B0.0% | $6.09B+7.4% | $5.67B+8.1% | ||
| $19.42B-28.3% | $27.09B+38.8% | $19.51B-2.2% | $19.95B+14.7% | ||
| $10.02B+503% | $1.66B-78.1% | $7.61B+3.8% | $7.33B-26.1% | ||
| 34%+28.3pp | 5.8%-22.3pp | 28%+1.2pp | 26.9%-9.5pp | ||
| $1.03B+4.8% | $978M+3.6% | $944M+1.0% | $935M-6.6% | ||
| $798M— | —— | $199M+134% | -$581M+16.5% | ||
| $9.8B+1,320% | $690M-89.9% | $6.86B+18.0% | $5.81B-29.8% | ||
| $1.39B+559% | $211M-83.1% | $1.25B0.0% | $1.25B-39.9% | ||
| $8.51B+1,673% | $480M-91.5% | $5.66B+23.3% | $4.59B-26.2% | ||
| 28.9%+27.2pp | 1.7%-19.2pp | 20.9%+4.1pp | 16.8%-6.0pp | ||
| $6.77+1,730% | $0.37-91.8% | $4.49+23.0% | $3.65-26.0% | ||
| $10.39B+409% | $2.04B-78.9% | $9.7B+7.9% | $8.99B-12.3% | ||
| 35.3%+28.2pp | 7.1%-28.7pp | 35.8%+2.8pp | 32.9%-4.6pp | ||
| $10.02B+503% | $1.66B-78.1% | $7.61B+3.8% | $7.33B-26.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Gilead Sciences's revenue?
- Gilead Sciences (GILD) generated $29.7B in revenue over the trailing twelve months, up 3.5% year over year.
- Is Gilead Sciences profitable?
- Gilead Sciences reported $9.2B in net income over the trailing twelve months, a 31.0% net margin.
- What are Gilead Sciences's profit margins?
- Gross margin is 79.4% and operating margin is 34.9%, with a 31.0% net margin.
- What is Gilead Sciences's earnings per share?
- Gilead Sciences's diluted EPS over the trailing twelve months is $7.34.
- Where does Gilead Sciences's income statement data come from?
- Every line is extracted from Gilead Sciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
